Company history

Company history

1912 - 1918
1948 - 1980
1981 - 1994
1994 - 1998
1998 - 2013
From 2014 to presents

Directly after the Pasteur Institute was established in Paris, as the second is Europe, Dr. Köves János and Dr. Hutyra Ferenc founded the Phylaxia serum producer ltd. in 1912, which successfully started to produce -world’s first- serum against swine plague. After this, they developed and produced several serums against animal diseases, like rabies, distemper, smallpox, and poultry pox. In 1924, the production of human vaccines was started, with the manufacture of diphtheria-anatoxin, and the vaccines against tuberculosis and smallpox. After several acquisitions, at the middle 1930’s, the products of Phylaxia were available almost all across the globe, and gained international reputation for the company

In 1948, during the socialization, all the Hungarian vaccine-producer institutes were merged under the auspices of Phylaxia, but in 1952 the industry of human vaccine produce was separated. From the ’60, the development of large-scale stock farming requires a greater amount of veterinary medicines, therefore the demand for the company’s products also increased steadily. The Phylaxia mainly produced it’s vaccines to the domestic markets and to the COMECON countries, but the export to the Western European countries were also significant. Many specialists of the company, has been working with the WHO-FAO programs, in Morocco, Mongolia, Egypt, Lebanon, Syria, and Cuba

From 1981, the focus stays on veterinary medicine production. In 1987, from the loan which provided by the World Bank, one of Europe’s most modern fermentation facility was built. Due to the indebtedness of this project, the management had to solve aggravating financial problems. In 1991, due the privatization of the company, the vaccine production has moved to the Phylaxia Sanofi ltd.; which was founded by Sanofi Sante Nutrition Animale (SSNA), the Chinoin ltd. and Phylaxia. But the debt of the fermentation facility project remained with the Phylaxia in 100%. The financially critical situation of Phylaxia resulted the selling to the fermentation plant, and the valuable business share owned in Phylaxia Sanofi joint venture.

The National Asset Management Inc. transformed the company into a LLC (limited liability company) in 1994. The company were sold to one of its domestic competitors, the Bábolna Pharma Rt., after its financial reorganization, by Bankár kft, which previously made the company’s privatization. In order of more efficient operation, the owners decided the fusion of the two companies, during which the Bábolna Pharma Rt merged in Phylaxia Rt with all it’s assets. After the fusion, the company’s name been changed to Phylaxia Pharma Rt., which became the sole successor of the internationally renowned Phylaxia Szérumtermelő Rt. On April 22, 1998, the Phylaxia Pharma Rt.’s stocks are introduced to the Budapest Stock Exchange of the traded shares’ “B” category.

Between 1999 and 2002, due to the decrease of incomes, a radical reorganization programme were implemented. The company started the configuration if its holding structure, changed its name to PHYLAXIA 1912. Holding Nyrt., and cease its veterinary activities in 2009. In 2011, the management transformed due to the main aspect of rationalization and portfolio purification. The consortium decided to sell the low- capital, dormant subsidiaries, whose potential market share were marginal. In 2013, the consortium expanded with new, more profitable companies, and continued its operations under new name as OPIMUS GROUP Nyrt.

After the change of corporate image, the company primarily deals with management and trusteeship of companies with different profiles as a financial investor in holding structure. At this point the company’s subsidiaries includes a newspaper publisher, a stove and fireplace factory, an agricultural company and a construction firm, as also an office renting and managing company. The management changed he company’s name to OPUS GLOBAL Nyrt in 2017, through which they wanted to emphasize the company’s new structure and potential, and at the same time, to give a new image. In 2017, the company’s shares are listed as premium in the Budapest Stock Exchange. The company is constantly expanding its investment